School of Pharmaceutical Sciences, Sun Yat-sen University, China.
Br J Clin Pharmacol. 2010 Aug;70(2):234-40. doi: 10.1111/j.1365-2125.2010.03698.x.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Genetic polymorphisms of VKORC1 and CYP2C9 are known to influence warfarin dosage. * Recent studies among Caucasians showed that polymorphisms of CYP4F2 also play a role in warfarin pharmacogenetics. * The contribution of CYP4F2 variants to the variability inwarfarin dose requirement in Chinese subjects remains to be investigated. WHAT THIS STUDY ADDS * This research was to study the effect of CYP4F2 variants on warfarin requirements in the Han Chinese population. * This study developed a multiple regression model including CYP2C9, VKORC1 3673G>A, CYP4F2 genotypes and age, weight, combination use of amiodarone which could explain 56.1% of the individual variability in warfarin dose CYP4F2 could explain 4% of the variance in warfarin dose. * We found that one novel genotypic polymorphism 5417G>T for Asp36Tyr, which was identified as an important marker of warfarin resistance, was absent in the Han Chinese population in our study. AIMS The objective of this study was to assess the effect of the CYP4F2 on the daily stable warfarin dose requirement in Han Chinese patients with mechanical heart valve replacement (MHVR). METHODS From March 2007 to November 2008, 222 Han Chinese MHVR patients were recruited in our study. VKORC1 3673G>A, 5417G>T, CYP2C9*3 and CYP4F2 rs2108622 were genotyped by using the polymerase chain reaction restriction fragment length polymorphism method (PCR-RFLP). Polymorphisms of VKORC1 9041G>A were detected by direct sequencing. Multiple linear regression analysis was used to investigate the contribution of CYP4F2. RESULTS The CYP4F2 rs2108622 CT/TT group took a significantly higher stable warfarin dose (3.2 mg day(-1)) than the CC group (2.9 mg day(-1), 95% CI 0.2, 1.0, P= 0.033). The multiple linear regression model included VKORC1 3673G>A, CYP2C9, CYP4F2 genotypes and clinical characteristics. The model could explain 56.1% of the variance in stable warfarin dose in Han Chinese patients with MHVR. CYP4F2 contributed about 4% to the variance in the warfarin dose. There was no variation in the SNPs of VKORC1 5417G>T. CONCLUSION CYP4F2 is a minor significant factor of individual variability in the stable warfarin dose in Han Chinese patients with MHVR. The effect of CYP2C9 and VKORC1 genotypes on variability in the stable warfarin dose had also been confirmed.
已知本研究领域的相关信息 * 已知 VKORC1 和 CYP2C9 的基因多态性会影响华法林的剂量。 * 最近的白种人群研究表明,CYP4F2 的基因多态性也在华法林药物遗传学中发挥作用。 * CYP4F2 变体在中国人群中对华法林剂量需求的变异性的贡献仍有待研究。 本研究的新增内容 * 本研究旨在研究 CYP4F2 变体对汉族人群华法林需求的影响。 * 本研究开发了一个包含 CYP2C9、VKORC1 3673G>A、CYP4F2 基因型和年龄、体重、胺碘酮联合使用的多元回归模型,该模型可以解释华法林剂量个体差异的 56.1%。 CYP4F2 可以解释华法林剂量变异性的 4%。 * 我们发现,一种新的基因型多态性 5417G>T 对 Asp36Tyr,这被确定为华法林耐药的重要标志物,在我们的研究中汉族人群中不存在。 目的 本研究的目的是评估 CYP4F2 对汉族机械性心脏瓣膜置换术(MHVR)患者稳定的华法林日剂量需求的影响。 方法 2007 年 3 月至 2008 年 11 月,我们研究纳入了 222 名汉族 MHVR 患者。使用聚合酶链反应限制片段长度多态性(PCR-RFLP)方法检测 VKORC1 3673G>A、5417G>T、CYP2C9*3 和 CYP4F2 rs2108622。直接测序检测 VKORC1 9041G>A 的多态性。采用多元线性回归分析探讨 CYP4F2 的贡献。 结果 CYP4F2 rs2108622 CT/TT 组稳定华法林剂量(3.2mg/d)明显高于 CC 组(2.9mg/d,95%CI 0.2,1.0,P=0.033)。多元线性回归模型包括 VKORC1 3673G>A、CYP2C9、CYP4F2 基因型和临床特征。该模型可以解释汉族 MHVR 患者稳定华法林剂量变异性的 56.1%。CYP4F2 对华法林剂量的变异性贡献约为 4%。VKORC1 5417G>T 的 SNP 无变化。 结论 CYP4F2 是汉族 MHVR 患者稳定华法林剂量个体差异的一个次要显著因素。CYP2C9 和 VKORC1 基因型对稳定华法林剂量变异性的影响也得到了证实。